Drug intelligence / Profile preview

KAR-x

Development stage: Preclinical
Lead developer: Kardigan

Overview

KAR-x is an early-stage therapeutic candidate currently in the discovery phase of development by Kardigan (Kardigan Bio). As of the latest pipeline disclosures, the specific biological targets, therapeutic modalities, and primary disease indications for KAR-x remain proprietary and have not been publicly disclosed. The asset represents a component of Kardigan's internal research and development pipeline focused on novel therapeutic interventions.

Targets

TUBB (Tubulin (alpha and beta subunits))CaM (Calmodulin)

Beyond the preview

Go deeper on KAR-x.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAR-x.

Explore the full profile